The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes

Drugs of Today

Volumn 43, Issue 11, 2007, Pages 815-826

  Triggle, Chris R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 METHYLTETRAHYDROFOLIC ACID; ADVANCED GLYCATION END PRODUCT; ALPHA GLUCOSIDASE INHIBITOR; ANTIOXIDANT; BIGUANIDE DERIVATIVE; CANNABIDIOL; CANNABINOID; CJC 1131; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCRETIN; INSULIN; INSULIN SENSITIZING AGENT; LIRAGLUTIDE; MEGLITINIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN KINASE C; SEPIAPTERIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TETRAHYDROBIOPTERIN; VILDAGLIPTIN;

BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; DATA ANALYSIS; DIET; DISEASE ASSOCIATION; DRUG TARGETING; ENDOTHELIUM; ENZYME ACTIVATION; EXERCISE; GENETIC LINKAGE; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HEALTH STATUS; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MORBIDITY; MORTALITY; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PROTEIN PHOSPHORYLATION; RETINOPATHY; REVIEW; SIGNAL TRANSDUCTION; WORLD HEALTH ORGANIZATION;

ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; HYPOGLYCEMIC AGENTS; POSTPRANDIAL PERIOD;

EID: 38349049629     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.11.1120870     Document Type: Review

References (98)

1. Mobbs, C.V., Isoda, F., Makimura, H. et al. Impaired glucose signaling as a cause of obesity and the metabolic syndrome: the glucoadipostatic hypothesis. Physiol Behav 2005, 85(1): 3-23.
2. Andrews, K.L., Pannirselvam, M., Anderson, T.J. et al. The vascular endothelium in diabetes: a practical target for drug treatment? Expert Opin Ther Targets 2005, 9(1): 101-17.
3. Anderson, T.J., Uehata, A., Gerhard, M.D. et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995, 26(5): 1235-41.
4. Triggle, C.R., Howarth, A., Cheng, Z.J. et al. Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): Does a dysfunctional endothelium contribute to the development of type 2 diabetes? Can J Physiol Pharmacol 2005, 83(8-9): 681-700.
5. Neel, J.V. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962, 14: 353-62.
6. Zimmet, P. Globalization, coca-colonization and the chronic disease epidemic: Can the Doomsday scenario be averted? J Intern Med 2000, 247(3): 301-10.
7. Diamond, J. The double puzzle of diabetes. Nature 2003, 423(6940): 599-602.
8. Surwit, R.S., Feinglos, M.N., Rodin, J. et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism. 1995, 44: 645-51.
9. Hill, M.A., Ege, E.A. Active and passive mechanical properties of isolated arterioles from STZ-induced diabetic rats. Effect of aminoguanidine treatment. Diabetes 1994, 43(12): 1450-6.
10. Soldatos, G., Cooper, M.E. Advanced glycation end products and vascular structure and function. Curr Hypertens Rep 2006, 8(6): 472-478.
11. Ceriello, A. Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 2005, 54(1): 1-7.
12. Leiter, L.A., Ceriello, A., Davidson, J.A. et al. International Prandial Glucose Regulation Group (PGR). Postprandial glucose regulation: new data and new implications. Clin Ther 2005, 27(Suppl. B): S42-S56.
13. Avignon, A., Radauceanu, A., Monnier, L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997, 20(12): 1822-6.
14. Johnson, J.H. Trends and opportunities in the metabolic syndrome. Drug Dev Res. 2006, 67: 539-44.
15. Azuma, K., Watada, H., Otsuka, A. et al. Repetitive glucose spikes enhances monocyte adhesion to endothelial cells more than consistent hyperglycemia in rat thoracic artery. Diabetes 2005, 54(Suppl. 1): A188.
16. Otsuka A, Azuma K, Iesaki T. et al. Temporary hyperglycemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia. 2005, 48(12): 2667-74.
17. Liu, Y., Terata, K., Rusch, N.J. et al. High glucose impairs voltage-gated K(+) channel current in rat small coronary arteries. Circ Res 2001, 89(2): 146-52.
18. Rainbow, R.D., Hardy, M.E., Standen, N.B. et al. Glucose reduces endothelin inhibition of voltage-gated potassium channels in rat arterial smooth muscle cells. J Physiol. 2006, 575(Pt. 3): 833-44.
19. + channels in rabbit myogenic cerebral arteries. Am J Physiol. 1995, 269(1 Pt. 2): H348-55.
20. Cole, W.C., Chen, T.T., Clement-Chomienne, O. Myogenic regulation of arterial diameter: role of potassium channels with a focus on de layed rectifier potassium current. Can J Physiol Pharmacol 2005, 83(8-9):755-65.
21. Straub, S.V., Nelson, M.T. A spoonful of sugar helps the KV channel activity go down. J Physiol 2006, 575(Pt. 3): 691.
22. + channels by high glucose. Circ Res. 2006, 99(6): 607-616.
23. Kawano, H., Motoyama, T., Hirashima, O. et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999, 34(1): 146-154.
24. Ihlemann, N., Rak-Madsen, C., Perner, A et al. Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. Am J Physiol Heart Circ Physiol 2003, 285(2): H875-82.
25. Alp, N.J., Channon, K.M. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004, 24(3): 413-20.
26. Roe, M.W., Worley, J.F., Mital, A.A. et al. Expression and function of pancreatic beta-cell delayed rectifier K+ channels. Role in stimulus-secretion coupling. J Biol Chem 1996, 271(50): 32241-6.
27. MacDonald, P.E., Sewing, S., Wang, J. et al. Inhibition of Kv2.1 voltage-dependent K+ channels in pancreatic beta-cells enhances glucose-dependent insulin secretion. J Biol Chem 2002, 277(47): 44938-45.
28. Krauss, S., Zhang, C.-Y., Scorrano, L. et al. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest 2003, 112(12): 1831-142.
29. Brownlee, M. A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest 2003, 112(12): 1788-90.
30. Pannirselvam, M., Simon, V., Sharma, S. et al. Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. Br J Pharmacol 2003, 140: 701-6.
31. McCarty, M.F. Oster rediscovered - Mega-dose folate for symptomatic atherosclerosis. Med Hypotheses. 2007 Jan 12; e-pub.
32. Moens, A.L., Kass, D.A. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 2006, 26(11): 2439-2444. Review.
33. Trefz, F.K., Aulela-Scholz, C., Blau, N. Successful treatment of phenylketonuria with tetrahydrobiopterin. Eur J Pediatr 2001, 160(5): 315.
34. Zurfluh, M.R., Fiori, L., Fiege, B. et al. Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. J Inherit Metab Dis 2006, 29(6): 725-731.
35. Hyndman, M.E., Verma, S., Rosenfeld, R.J. et al. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol 2002, 282(6): H2167-72.
36. Tanner, F.C., van der Loo, B., Shaw, S. et al. Inactivity of nitric oxide synthase gene in the atherosclerotic human carotid artery. Basic Res Cardiol 2007 [Epub ahead of print].
37. Hurlimann, D., Noll, G., Gatti, C.D. et al. Oral treatment with tetrahydrobiopeterin reverses endothelial dysfunction and oxidative stress in hypercholesterolemia. Circulation 2005, 112; U192-3.
38. Ellis, A., Triggle, C.R. Endothelium-derived reactive oxygen species: Their relationship to endothelium-dependent hyperpolarization and vascular tone. Can J Physiol Pharmacol 2003, 81(11): 1013-28.
39. Nishikawa, T., Edelstein, D., Du, X.L. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature. 2000, 404(6779): 787-790.
40. Bagi, Z., Toth, E., Koller, A. et al. Microvascular dysfunction after transient high glucose is caused by superoxide-dependent reduction in the bioavailability of NO and BH(4). Am J Physiol Heart Circ Physiol 2004, 287(2): H626-33.
41. Zhao, K., Zhao, G.M., Wu, D. et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004, 279(33): 34682-90.
42. Szeto, H.H. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J. 2006, 8(2): E277-83.
43. Thomas, D.A., Stauffer, C., Zhao, K. et al. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplanta tion function. J Am Soc Nephrol 2007, 18(1): 213-22.
44. Chen, Y., Buck, J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther 2000, 293(3): 807-812.
45. Rajesh, M., Mukhopadhyay, P., Batkai, S. et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 2007, Mar 23; [Epub ahead of print].
46. Barnes, M.P. Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006, 7(5): 607-615.
47. Pacher, P., Batkai, S Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58(3): 389-462.
48. Morino, K., Petersen, K.F., Dufour, S. et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 2005, 115(12): 3587-93.
49. Petersen, K.F., Befroy, D., Dufour, S. et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003, 300(5622): 1140-1142.
50. Menshikova, E.V., Ritov, V.B., Fairfull, L. et al. Effects of exercise on mitochondrial content and function in aging human skeletal muscle. J Gerontol A Biol Sci Med Sci 2006. 61(6): 534-40.
51. Ritov, V.B., Menshikova, E.V., He, J. et al. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005, 54(1): 8-14.
52. Bjelakovic, G., Nikolova, D., Gluud, L.L. et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007, 297(8): 842-857.
53. Guzik, T.J., West, N.E., Black, E. et al. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res 2000, 86(9): E85-90.
54. Dusting, G.J., Triggle, C. Are we over oxidized? Oxidative stress, cardiovascular disease, and the future of intervention studies with antioxidants. Vasc Health Risk Manag 2005,1(2): 93-7.
55. Silver, A.E., Beske, S.D., Christou, D.D. et al. Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47(phox) expression and evidence of endothelial oxidative stress. Circulation 2007, 115(5): 627-37.
56. Eriksson, K.F., Lindgarde, F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus with life-style intervention or metformin. New England J. Med. 346: 393-403.
57. by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia. 1991, 34(12): 891-8.
58. Pan, X.R., Yang, W.Y., Li, G.W. et al. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care 1997, 20(11):1664-9.
59. Tuomilehto, J., Lindstrom, J., Eriksson, J.G. et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344(18): 1343-50.
60. Diabetes Prevention Research Group. Reduction in the evidence of type 2 diabetes with lifestyle intervention or metformin. N. Eng J Med 2002, 346: 393-403
61. Brownell, K.D., Wadden, T.A. Etiology and treatment of obesity: understanding a serious, prevalent, and refractory disorder. J Consult Clin Psychol 1992, 60(4): 505-517.
62. Daniels, J. Obesity: America's epidemic. Am J Nurs 2006, 106(1): 40-9, quiz 49-50.
63. Pedersen, S.D., Kang, J., Kline, G.A. Portion control plate for weight loss in obese patients with type 2 diabetes mellitus: a controlled clinical trial. Arch Intern Med 2007, 167(12): 1277-83.
64. Maiorona, A., O'Driscoll, G., Cheetam, C. et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol 2001, 38: 860-866.
65. Eskurza I, Myerburgh LA, Kahn ZD, et al. Tetrahydrobiopterin augments endothelium-dependent dilatation in sedentary but not in habitually exercising older adults. J Physiol. 2005, 568(Pt. 3):1057-1065.
66. Focardi, M., Dick, G.M., Picchi, A. et al. Restoration of Coronary Endothelial Function In Obese Zucker Rats By A Low Carbohydrate Diet. Am J Physiol Heart Circ Physiol. 2007, Jan 12; [Epub ahead of print].
67. Sigal, R.J., Kenny, G.P., Boule, N.G. et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007, 147(6): 357-369.
68. Ding, H., Aljofan, M., Triggle, CR. Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. J Cell Physiol 2007, in press.
69. Rendell, M.S., Jovanovic, L. Targeting postprandial hyperglycemia. Metabolism 2006, 55(9): 1263-1281.
70. Chiasson, J.L., Josse, R.G., Gomis, R. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NID-DM trial. JAMA 2003, 290(4): 486-94.
71. Hanefeld, M., Cagatay, M., Petrowitsch, T. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J 2004, 25(1): 10-6.
72. Azuma, K., Toyofuku, Y., Iesaki, T. et al. Acarbose, an α-glucosidase inhibitor, impoves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetititive blood glucose fluctuation. Biochem Biophys Res Commun 2006, 345(2): 688-93.
73. van de Laar, F.A., Lucassen, P.L., Akkermanns, R.P. et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005, 28(1): 154-63.
74. Inoue, I., Shinoda, Y., Nakano, T. et al. Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism 2006, 55(7): 946-52.
75. Rudofsky, G. Jr., Reismann, P., Schiekofer, S. et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res 2004, 36(9): 630-8.
76. Berger, J.P., Akiyama, T.E., Meinke, P.T. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005, 26(5): 244-51.
77. Mudaliar, S., Chang, A.R., Henry, R.R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology and clinical implications. Endocrine Pract 2003, 9: 406-416.
78. King, K.A., Levi, V.E. Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione. Am J Health Syst Pharm 2004, 61(4): 390-3.
79. Klaman, L.D., Boss, O., Peroni, O.D. et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 2000, 20(15): 5479-89.
80. Klupa, T., Malecki, M.T., Pezzolesi, M. et al. Further evidence for a susceptibility locus for type 2 diabetes on chromosome 20q13.1-q13.2. Diabetes 2000, 49(12): 2212-6.
81. La Barre, J. Sur les possibilités d'un traitement du diabète par l'incrétine. Bull Acad R Med Belg 1932, 12: 620-34.
82. Strader, A.D., Woods, S.C. Gastrointestinal hormones and food intake. Gastroenterology 2005, 128(1): 175-191.
83. Drucker, D.J. The biology of incretin hormones. Cell Metab 2006, 3(3): 153-65.
84. Gallwitz, B. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud 2005, 2(2): 61-9.
85. Buteau, J., Roduit, R., Susini, S. et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999, 42(7): 856-64.
86. Zhou, J., Wang, X., Pineyro, M.A. et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999, 48(12): 2358-66.
87. Young, A.A., Gedulin, B.R., Bhavsar, S. et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999, 48(5): 1026-34.
88. Giannoukakis, N. CJC-1131. ConjuChem. Curr Opin Investig Drugs 2003, 4(17): 1245-9.
89. Leger, R., Thibaudeau, K., Robitaille, M. et al. Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg Med Chem Lett 2004. 14: 4395-8.
90. Vilsboll, T. Liraglutide: A once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus. Expert Opin Investig Drugs 2007, 16(2): 231-237.
91. Aytac, U., Dang, N.H. CD26/dipeptidyl peptidase IV: A regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord 2004, 4(1):11-8.
92. Marguet, D., Baggio, L., Kobayashi, T. et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000, 97(12): 6874-9.
93. Drucker, D.J., Nauck, M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006, 368(9548): 1696-705.
94. Drucker, D., Easley, C., Kirkpatrick, P. Sitagliptin. Nature Reviews Drug Discovery 2007, 6: 109-110.
95. Von Geldern, T.W., Trevillyan, J.M. "The Next Big Thing" in Diabetes: Clinical Progress on DPP-IV Inhibitors. Drug Dev Res 2006, 67: 627-642.
96. Grouzmann, E., Buclin, T., Biollaz, J. Gliptins. Lancet 2007, 369(9558): 269.
97. Lefebvre, J., Murphey, L.J., Hartert, T.V. et al. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angiodema. Hypertension 2002, 39(2 Pt. 2): 460-4.
98. Henness, S., Keam, S.J. Vildagliptin. Drugs 2006, 66: 1989-2001; discussion 2002-2004.